Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cell Mol Neurobiol ; 41(1): 129-150, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-32303879

RESUMO

BACKGROUND AND AIM: Thimerosal (THIM) is a mercury-containing preservative widely used in many biological and medical products including many vaccines. It has been accused of being a possible etiological factor for some neurodevelopmental disorders such as autistic spectrum disorders (ASDs). In our study, the potential therapeutic effect of montelukast, a leukotriene receptor antagonist used to treat seasonal allergies and asthma, on THIM mice model (ASDs model) was examined. METHODOLOGY: Newborn mice were randomly distributed into three groups: (Group 1) Control (Cont.) group received saline injections. (Group 2) THIM-treated (THIM) group received THIM intramuscular (IM) at a dose of 3000 µg Hg/kg on postnatal days 7, 9, 11, and 15. (Group 3) Montelukast-treated (Monte) group received THIM followed by montelukast sodium (10 mg/kg/day) intraperitoneal (IP) for 3 weeks. Mice were evaluated for growth development, social interactions, anxiety, locomotor activity, and cognitive function. Brain histopathology, alpha 7 nicotinic acetylcholine receptors (α7nAChRs), nuclear factor kappa B p65 (NF-κB p65), apoptotic factor (Bax), and brain injury markers were evaluated as well. RESULTS: THIIM significantly impaired social activity and growth development. Montelukast mitigated THIM-induced social deficit probably through α7nAChRs upregulation, NF-κB p65, Bax, and brain injury markers downregulation, thus suppressing THIM-induced neuronal toxicity and inflammation. CONCLUSION: Neonatal exposure to THIM can induce growth retardation and abnormal social interactions similar to those observed in ASDs. Some of these abnormalities could be ameliorated by montelukast via upregulation of α7nAChRs that inhibited NF-κB activation and significant suppression of neuronal injury and the associated apoptosis.


Assuntos
Acetatos/uso terapêutico , Transtorno Autístico/induzido quimicamente , Transtorno Autístico/tratamento farmacológico , Ciclopropanos/uso terapêutico , Quinolinas/uso terapêutico , Comportamento Social , Sulfetos/uso terapêutico , Timerosal/administração & dosagem , Timerosal/efeitos adversos , Acetatos/administração & dosagem , Acetatos/farmacologia , Animais , Animais Recém-Nascidos , Transtorno Autístico/patologia , Ciclopropanos/administração & dosagem , Ciclopropanos/farmacologia , Crescimento e Desenvolvimento/efeitos dos fármacos , Hipocampo/patologia , Hipocampo/ultraestrutura , Camundongos , Proteínas do Tecido Nervoso/metabolismo , Quinolinas/administração & dosagem , Quinolinas/farmacologia , Sulfetos/administração & dosagem , Sulfetos/farmacologia , Fator de Transcrição RelA/metabolismo , Receptor Nicotínico de Acetilcolina alfa7/metabolismo
2.
Opt Lett ; 37(11): 1835-7, 2012 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-22660045

RESUMO

The process of spontaneous emission can be dramatically modified by optical microstructures and nanostructures. We have studied the modification of fluorescence dynamics using a variable thickness polymer spacer layer fabricated using layer-by-layer self-assembly with nanometer accuracy. The change in fluorescence lifetime with spacer layer thickness agrees well with theoretical predictions based on the modified photonic density of states (PDOS), and yields consistent values for the fluorophores' intrinsic fluorescence lifetime and quantum yield near a dielectric as well as a plasmonic interface. Based on this observation, we further demonstrate that self-assembled fluorophores can be used to probe the modified PDOS near optical microstructures and nanostructures.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...